BioMarin Announces Appointment of Ian T. Clark to Board of Directors

Core Insights - BioMarin Pharmaceutical Inc. has appointed Ian T. Clark to its Board of Directors effective August 1, 2025 [1] - Ian T. Clark previously served as CEO of Genentech, where he led the launch of 15 new drugs [2] - Clark has extensive experience in the biopharmaceutical industry, having held senior roles at Novartis, Sanofi, Ivax Pharmaceuticals, and G.D. Searle [2] - The addition of Clark is expected to bring valuable perspective to BioMarin, enhancing its ability to develop new therapies for patients with unmet needs [3] Company Overview - BioMarin is a global biotechnology company focused on developing medicines for rare and difficult-to-treat genetic conditions [4] - Founded in 1997 and based in San Rafael, California, BioMarin has a strong track record with eight commercial therapies and a robust clinical and preclinical pipeline [4] - The company aims to translate genetic discoveries into impactful medicines for patients worldwide [4]